NSE · PANACEABIO · Pharmaceuticals
Panacea Biotec Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹111 Cr with net profit ₹-0 Cr — a -0.16% net margin, versus -7.41% the period before.
Shareholding
As of 2026-06-30
- Promoter72.48%
- Public22.96%
- FII2.31%
- DII2.25%
33,532 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.21× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #43 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,444 Cr | 176.1 | 5.71 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,990 Cr | 88.75 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,885 Cr | 19.67 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,077 Cr | 192.91 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,246 Cr | 88.01 | 18.16 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,344 Cr | 431.06 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,388 Cr | 100.3 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,837 Cr | 545.38 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,823 Cr | 286.92 | 4.91 | 16.66% | 15.65% |
| Panacea Biotec Ltd.(this company) | ₹2,596 Cr | 5298.13 | 3.11 | -2.93% | -0.84% |
AI analysis
AI-generated · google/gemini-2.5-flashPanacea Biotec Ltd. has a market capitalization of Rs 3362 Cr and a current PE ratio of 6860.63. The company reported a revenue of Rs 579.75 Cr. The book value is Rs 136.3, with an EPS of 0. Promoter holding stands at 72.4794%.
Positives
- +The debt-to-equity ratio is low at 0.02, suggesting limited financial leverage.
- +Promoter holding is substantial at 72.4794%, demonstrating significant insider ownership.
- +No promoter shares are reported as pledged (0%).
Negatives
- −The company has a negative Return on Equity (ROE) of -292.7%.
- −The Return on Capital Employed (ROCE) is negative at -2.4218%.
- −The profit margin is significantly negative at -83.9%.
- −Earnings Per Share (EPS) is 0, indicating no earnings per share for shareholders.
- −The company has reported negative Net Profit in four out of the last five quarterly periods, with values as low as -13.92 Cr (Sept 2025).
Financial performance
Panacea Biotec Ltd. reported a total revenue of Rs 579.75 Cr. The profit margin for the company is -83.9%. Over the last five reported annual periods, revenue ranged from Rs 67.9 Cr (Mar 2025) to Rs 112.25 Cr (Jun 2025). The company recorded negative net profits in all five reported annual periods, with figures ranging from -0.18 Cr (Mar 2026) to -15.64 Cr (Sept 2025).
Profitability & returns
The company's profitability metrics show a Return on Equity (ROE) of -292.7% and a Return on Capital Employed (ROCE) of -2.4218%. The Earnings Per Share (EPS) is reported as 0. The profit margin currently stands at -83.9%.
Balance sheet
Panacea Biotec Ltd. has a low debt-to-equity ratio of 0.02, indicating a limited reliance on debt financing. The book value per share is Rs 136.3. There are no reported pledges by promoters.
Ownership & pledges
Public shareholders own 23.9594% of the shares. Institutional holding includes 1.9659% by DIIs and 1.5953% by FIIs. The company has no reported promoter share pledges.
Quarterly performance
In the latest reported quarter ending Mar 2026, the company generated revenue of Rs 166.75 Cr and a net profit of Rs 0.52 Cr. Over the last five quarters, net profit has fluctuated, ranging from -13.92 Cr (Sept 2025) to 4.52 Cr (Dec 2024).
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.